Menu
Not yet recruiting NCT07534397

Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation

No phase Interventional PARKINSON DISEASE (Disorder)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: transcranial direct current stimulation, Sham transcranial direct current stimulation.
Who it may be relevant to
Registry conditions: PARKINSON DISEASE (Disorder). Basic parameters: 50 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The purpose of this research study is to examine the effects of transcranial Direct Current Stimulation (tDCS) on verbal retrieval and cognition and sensorimotor control and to determine if tDCS can be used as a way to improve retrieval, sensory, and motor abilities in individuals with Parkinson's disease (PD).

Detailed description

Objective: Based on models of semantic memory retrieval developed, under which the pre-supplementary motor area (preSMA) of the dorsomedial frontal lobes play an important role, the study will examine the treatment of cognitive deficits in PD with HD tDCS applied to the preSMA to improve function in neural circuits supporting verbal retrieval. In addition, as the preSMA is implicated in motor planning and sequencing, the study also will explore whether HD tDCS applied to the preSMA will have an effect on speech and gait.

Specific Aims:

1. Examine the therapeutic effects on verbal retrieval function by modulating the preSMA using HD tDCS. 2. Examine the therapeutic effects on speech production and processing by modulating the preSMA using HD tDCS 3. Examine the therapeutic effects on gait and balance by modulating the preSMA using HD tDCS

Hypotheses:

1. : Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve verbal fluency (i.e, phonemic and category fluency on Controlled Word Association Test) as primary outcome measures. 2. : Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve speech sequencing. 3. : Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve general motor sequencing

Interventions

  • Device transcranial direct current stimulation
    Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seco
  • Device Sham transcranial direct current stimulation
    Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds

Primary outcome measures

  • Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency [Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment]
  • Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency [Time frame: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment]
  • Treatment group differences in change from Baseline to 1-week Post-Treatment on Phonemic Fluency [Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment]
  • Treatment group differences in change from Baseline to 2-months Post-Treatment on Phonemic Fluency [Time frame: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-months Post-Treatment]
Secondary outcome measures (12)
  • Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during overt reading [Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment]
  • Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during overt reading [Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment]
  • Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during self-generated speech [Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment]
  • Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during self-generated speech [Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment]
  • Treatment group differences in change from Baseline to 1-week Post-treatment on Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score. [Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment]
  • Treatment group differences in change from Baseline to 2-month Post-treatment on Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score. [Time frame: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment]
  • Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during overt reading [Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment]
  • Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during overt reading [Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment]
  • Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during self-generated speech [Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment]
  • Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during self-generated speech [Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment]
  • Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during overt reading [Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment]
  • Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during overt reading [Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment]

Eligibility criteria

Inclusion criteria

  • Diagnosed with PD having a verbal fluency deficit based on neuropsychological test (T-score < 40 or a T-score <-1.0 SD below the average T-score): Semantic Object Retrieval Test (SORT), COWAT (both letter and category fluency), Boston Naming Test (BNT), Rey Auditory Verbal Learning Test (RAVLT)
  • 50 - 90 years old
  • Capable of understanding and signing an informed consent (able to answer consent comprehension questions)
  • Fluent in speaking and reading English

Exclusion criteria

A potentially study-confounding, tDCS-contraindicated, or EEG-contraindicated psychological, neuropsychiatric, neurological, or other medical issues:

  • Montreal Cognitve Assessment (MOCA) score <23, unless an accompanying study partner/caregiver is with them and we can obtain the written consent of both the participant and the participant's accompanying study partner/caregiver (i.e., the participant's spouse, adult child, parent, or adult sibling);
  • history of seizures;
  • unexplained episodes of loss of consciousness (as these may be related to brain alterations or epilepsy);
  • suffering from severe or frequent headaches;
  • unstable or uncontrolled neuropsychiatric illness;
  • severe traumatic brain injury (based on the Ohio State TBI Identification; Method);
  • brain tumor; stroke; present drug abuse/misuse;
  • brain tumor;
  • serious or life-threatening diseases, including congestive heart failure, chronic obstructive pulmonary disease, or active malignancy;
  • Huntington's disease;
  • stroke;
  • cranial implants or skull defects that affect tDCS administration;
  • implanted brain medical devices, including, deep brain stimulators (DBS);
  • implanted pacemakers;
  • any electrically, magnetically, or mechanically activated implants;
  • cardiac, neural, or medication implants;
  • vascular clips or other electrically sensitive support systems in the brain;
  • damaged skin at the sites of stimulation (the device should only be used on healthy, intact skin, as wounds may alter resistance to current);
  • skin conditions such as dermatitis, psoriasis, or eczema;
  • pregnant women;
  • diagnosis of just dysarthria;

Use of medications that interact with or potentially interact with tDCS or EEG effects:

  • anti-convulsants;
  • carbamazepine;
  • sulpiride;
  • pergolide;
  • lorazepam;
  • rivastigmine;
  • dextromethorphan;
  • D-cycloserine;
  • flunarizine;
  • ropinirole;
  • citalopram;
  • stimulants;

Additionally, non-English speakers will be excluded because not all of the screening forms, questionnaires, and tests are available in languages other than English.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Callier Clinical Center, The University of Texas at Dallas — Richardson

Identifiers

NCT: NCT07534397 · IRB-26-35

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗